anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
It was planned as a non-invasive reliability study. The validity and reliability of 6PBRT in obese individuals will be investigated within the scope of the study. In this context, a 1-hour rest break will be given after the first test. Dyspnea and fatigue will be evaluated using the Borg scale and muscle oxygenation, heart rate and blood pressure will be recorded before and after 6PBRT. The second trial of 6PBRT will be performed after the 1-hour rest period. In order to ensure that the patients are stable, the level of dyspnea and fatigue and the initial values of heart rate will be checked before the second trial. All evaluations will be made by the same physiotherapist and an expert physiotherapist will be present during the evaluations.

The smallest sample size of the study was found to be 40 people with a correlation coefficient of 0.95 between the two tests and 90% power at a 95% confidence interval. It is aimed to include 50 people against a 20% drop-out risk.

Shapiro-Wilk test and histogram graphics will be used to check the normality of the data. Demographic and clinical characteristics of the participants will be reported using descriptive statistics. Intraclass correlation coefficient (ICC) with two-way random effects and absolute agreement methods will be used to assess test-retest reliability. The strength of reliability will be interpreted as excellent for ICC value \&amp;amp;amp;gt;0.90. Ninety-five percent Confidence Interval (95% CI) will be calculated to investigate measurement variability.
&lt;P&gt;PROBLEM TO BE SOLVED: To solve the problem that there are various methods in relation to a facial beauty cares but they are based on the caring of the skin in order to strictly expect the maintenance of the present condition of the skin or the temporary restoration of the skin and the substantial improvement of the skin is not achieved.  &lt;P&gt;SOLUTION: The blood flow of subcataneous blood capillaries becomes good and the metabolism of the skin becomes active by immersing a face in hot water with high carbonate concentration, of which the carbon dioxide gas is 500 ppm or above at 30°C or above, preferably for 5 min or above. By performing this face bathing method every day, the subcataneous blood capillaries are developed toward the skin to bring about the permanent improvement of the skin. A container having a goggle-like shape not closing a mouth or a nose or a container having a mask-like shape for spreading hot water with the high carbonate concentration to the whole of the face capable of performing nosal respiration is mounted on the face so that the face bathing by hot water with the high carbonate concentration is easily performed even by a person whose face can not immersed in water and hot water with the high carbonate concentration is injected in the container to hold the direct contact state of the skin of the face with hot water with the high carbonate concentration for 5 min or above. This method and this container device can be used in a facing upward state.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:To prepare a W/O type emulsion contg. fine and uniform particles having superior stability and low oil content by freezing an oil phase, an aq. phase and a surface active agent phase or a mixed phase of a surface active agent with a polyol, separately, pulverizing the frozen products, and warming or compressing the pulverized products. CONSTITUTION:75-97pts.wt. aq. phase, 2-20pts.wt. liquid oil having low m.p. such as neopentyl glycol dihexanoate, etc., and 1-5pts.wt. surface active agent phase comprising polyoxyethylene alkyl ether or a mixed phase comprising a surface active agent and a polyol, are frozen separately. Then, the frozen products are pulverized at &lt;=-80 deg.C to fine particles. A mixture of each fine particle is warmed at -60 deg.C--30 deg.C or compressed under &gt;=1.1atm., and stirred. The mixture is then warmed at -10-10 deg.C or compressed under &gt;=1.1atm., to produce thus W/O type emulsion. The emulsion produced by this process contains fine and uniform particles having superior stability. It is suited particularly to the production of cosmetics such as cream, milky lotion, etc. since any special component is not contained.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide compositions and methods for the treatment and diagnosis of cancer (particularly, lung cancer).  &lt;P&gt;SOLUTION: The illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer. Such polypeptide and/or polynucleotide may be used in pharmacological compositions (e.g. vaccines) for the diagnosis and treatment of lung cancer, and in other compositions.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To prevent the hydrolysis of an acetal or ketal linkage and thereby obtain a glycerin deriv. compsn. having an improved stability by adding an nonionic surfactant to a glycerin deriv. or a mixture of two or more glycerin derivs. CONSTITUTION:A glycerin deriv. compsn. having an improved stability and useful for a plasticizer, various additives, a solvent, etc., is obtd. by adding a nonionic surfactant of formula III (wherein R&lt;5&gt; is 8-36C alkyl or alkenyl; AO is 2-4C oxyalkylene; and a is an integer of 1-30) to a glycerin deriv. (an acetal or ketal) or a mixture of two or more glycerin derivs. represented by formula I or II (wherein R&lt;1&gt; to R&lt;4&gt; are each H, 1-4C alkyl, or 2-4C alkenyl). The amt. of the surfactant added, though variable with its application, is pref. 0.1-30 pts.wt. based on 100 pts.wt. the deriv.; for diluting with a solvent, the concn. of 0.5wt.% or higher is pref.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a detergent which can improve the detergency of strongly alkaline electrolytic water generated from an electrolytic water generator, and maintain the detergency for a long time, and strongly acidic electrolytic water which has a sterilizing effect and is used in a hospital.  &lt;P&gt;SOLUTION: An electrolytic water generator having a metal cylindrical electrode having corrosion resistant properties carrying a conductive catalytic coating, and a cylindrical diaphragm covering the outside of the cylindrical electrode is used to generate the strongly alkaline electrolytic water without contamination of NaCl for the purpose of washing, and the strongly acidic electrolytic water for the purpose of sterilization. These kinds of electrolytic water are used for the purposes respectively. Sodium metasilicate or sodium carbonate is added to the strongly alkaline electrolytic water as a buffering agent, which can maintain the detergency for a long time. The strongly acidic electrolytic water having the sterilizing effect can be obtained as high-purity electrolytic water, which can be kept at the pH3 or lower, and maintain the sterilizing effect for a long time.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
1387281 Poly-titanic acid and poly-zirconic acid gels C &amp; A LABORATORIES Inc 11 Jan 1972 1151/72 Heading C1A and C1N [Also in Divisions AS and C2] Gelatinous condensed ortho-acids of formula where M is Ti or Zr, are prepared by hydrolysis of ortho titanate or zirconate esters, e.g. the alkyl esters, or by hydrolysis of TiCl 4  or ZrCl 4 . In the latter case hydrolysis is preferably effected with ice, followed if desired by neutralization, e.g. with dilute ammonia; acidification of the suspension, e.g. with citric acid, may be carried out to give a precipitate of hydrated titanium or zirconium hydroxide. The products are used in sun-screen compositions.
The present invention relates to colon locating administrated dragon&#39;s blood preparation and its application, and belongs to the field of medicine prepare and application. The colon locating administrated dragon&#39;s blood preparation consists of dragon&#39;s blood 30-90 wt% and supplementary material 70-10 wt%, and the supplementary material includes one or several of filler, disintegrating agent and lubricant. The filler is starch, microcrystalline cellulose, dextrin or lactose; the disintegrating agent is CMS-Na or L-HPC; and the lubricant is magnesium or talcum powder. The preparation process includes producing intermediate product, and coating with colon coating or filling granule into colon coating. The present invention has the advantages of high curative effect, no toxic side effect, taking convenience, etc. and is used in treating chronic colitis.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide 3-substituted-2-(arylalkyl)-1-azabicycloalkane, a method of producing the same, and a therapeutic method using the compound.  &lt;P&gt;SOLUTION: The azabicycloalkane is azabicyclooctane or the like. The aryl group in the arylalkyl moiety thereof is a 3-pyridinyl moiety or a 5-pyrimidinyl moiety, and the alkyl group thereof is a 1-4C alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a functional group such as an amide. The compound exhibits activity at a nicotinic acetylcholine receptor (nAChR), particularly at an a7 nAChR subtype, and is useful in modulating neurotransmission and in the release of a ligand involved in neurotransmission. The compound is effective in preventing or treating conditions and disorders including central nerve system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, and is also effective in treating inflammation, autoimmune disorders, pain, and excess neovascularization (such as one associated with tumor growth).  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
1. A polymorphic form of 5- [4- [2- (N-methyl-N- (2- pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione, maleic acid salt (the Polymorph) characterised in that it provides: (i) an infra red spectrum containing peaks at 1752,1546,1154,621, and 602 cm&lt;-1&gt;; and/or (ii) a Raman spectrum containing peaks at 1751,1243 and 602 cm&lt;-1&gt;; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 144.7,153.2,157.1,170.7,172.0 and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 58, and 3.48 Angstroms. 2. A Polymorph according to claim 1, which provides an infra red spectrum substantially in accordance with Figure I. 3. A Polymorph according to claim 1 or claim 2, which provides a Raman spectrum substantially in accordance with Figure II. 4. A Polymorph according to any one of claims 1 to 3, which provides a solidstate nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I. 5. A Polymorph according to any one of claims 1 to 4, which provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or Table II. 6. A Polymorph according to any one of claims 1 to 5, in isolated form. 7. A Polymorph according to any one of claims 1 to 6, in pure form. 8. A Polymorph according to any one of claims 1 to 7, in crystalline form. 9. A process for preparing a Polymorph according to claim 1, characterised in that a solution of Compound (I) in denatured ethanol at an elevated temperature is cooled so as to provide crystallisation of the Polymorph after which the Polymorph is recovered from the denatured ethanol. 10. A pharmaceutical composition comprising an effective, non-toxic amount of a Polymorph according to claim 1 and a pharmaceutically acceptable carrier therefor. 11. A Polymorph according to claim 1, for use as an active therapeutic substance. 12. A Polymorph according to claim 1, for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof. 13. The use of Polymorph for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof. 14. A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Polymorph to a human or non-human mammal in need thereof.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new prophylactic for diabetes that is effective for prevention of diabetes and alleviation of its symptoms, particularly expectable to prevent type 2 diabetes and to alleviate the symptoms thereof.  &lt;P&gt;SOLUTION: It has been found that curdlan as a polysaccharide bearing β-1,3-glucoside bonds has a suppressive action on the elevation of glycemia that is very effective for prophylaxis of diabetes and for alleviation of the symptoms, and the prevention of type 2 diabetes and the alleviation of its symptoms can be expected by this actions of the above saccharide, thereby the diabetic prophylactic comprising the curdlan is created. In this invention, the curdlan is used in the form of an alkaline aqueous solution or is gelled therewith. Further, the curdlan is partially hydrolyzed in such a degree that the activity of the curdlan still remains and then is used. This diabetic prophylactic can be used as a medicinal preparation or by suitably adding to food products, or the like, for the prevention of diabetes or for the alleviation of the symptoms.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE:To obtain the subject monoclonal antibody, specifically reactive with an isozyme of brain myosin and useful for diagnosing, etc., cerebral neuropathy such as various cerebral tumors, senile encephalatropy or Alzheimer type encephalatropy causing a change in quality of cerebral neurons. CONSTITUTION:Bovine cerebral myosin is dissolved in a 0.5M saline solution and mixed with complete Freund&#39;s adjuvant at 1:1 ratio and the resultant emulsion is then subcutaneously injected to immunize a BALB/c mouse. After 9 days, lymph nodes in both popliteal fossa parts of the mouse are taken out to collect a lymphocyte therefrom. The resultant lymphocyte is then fused to a murine myeloma. The fused cell is cultured in an HAT culture medium to provide a hybridoma, which is then screened to select an antibody-producing clone. The selected clone is further cloned by a limiting dilution method, etc., and monocloned. The resultant monoclonal hybridoma is cultured in a culture medium to afford the objective monoclonal antibody specifically reactive with an isozyme of the brain myosin.
The invention provides sweet potato ball formerly named Fu-qing ipomoea ball, which is O in shape and Q in character. The cot material is prepared by mixing appropriate starch mother and son dumpling into the natural healthy food sweet potato, pinching together, wraping various kinds of fillings and rounding. With the special preparation process, the cot is soft and palatable with Q toughness, and the fillings express respective functions. The sweet potato ball provided by the invention has good color and taste, complement each other&#39;s advantages, beautiful in appearance, balanced nutrition, and is easy to absorb, endless in aftertaste, and deeper in meaning, wherein kinds of tastes in the ball are not named king; and the sweet potato ball not only represents local flavor, but also represents deeper significance, which implies team spirit and togetherness. Pardon can generate cohesion, and consensus and synergy can realize successfully grand prospect. There is provided a common saying in civil society: every dog has his day, and the good luck comes when we eat the sweet potato ball. The science tells us, being kind to communicate, understanding rally, and being physical and psychological health, thus the good luck can be come with our dream.
The present invention is directed to a compound of formula (I), wherein R represents a hydrogen atom or an acyl, aroyl or cycloalkylcarbonyl radical or a residue of formula (Ia); R1? represents an alkyl radical; R2? represents an aryl or heteroaryl radical, or R1? represents an alkylene chain attached to a carbon atom in an ortho position of the R2? aryl or heteroaryl radical relative to a carbon of the R2? aryl or heteroaryl radical linked to the propanoyl moiety; R3? represents a hydrogen atom or an alkyl, aryl, alkoxy or aryloxy radical; and R&#39; represents a hydrogen atom or an alkyl, aralkyl, acyl or aroyl radical; and the pharmaceutically acceptable salts thereof. The invention is also directed to the preparation of these compounds, pharmaceutical compositions comprising the compounds and methods for their pharmaceutical use.
PROBLEM TO BE SOLVED: To obtain an emulsified composition, excellent in dispersibility of a hydrophobic powder and further good in emulsion stability and feeling of use by blending the hydrophobic powder with a nonionic surfactant having a specific hydrophile-lipophile balance(HLB) value and a water-soluble polymer in a specified proportion. SOLUTION: This oil-in-water type emulsified cosmetic is obtained by using a nonionic surfactant having &lt;=12 HLB (0.01-10wt.%), a hydrophobic powder (0.1-20wt.%) and a water-soluble polymer (0.01-10wt.%) in combination. Furthermore, an alkyl-modified carboxyvinyl polymer (0.01-10wt.%) is preferably contained in the system. A Pluronic (R) type surfactant (0.01-10wt.%) is further blended therein to afford an emulsified composition, improved in emulsifiability and excellent in emulsification stability. For example, sorbitan monooleate or POE glycerol monostearate is cited as the nonionic surfactant having &lt;=12 HLB. Talc, a polyamide powder, etc., are cited as the hydrophobic powder and gum arabic, dextran, methyl cellulose, etc., are cited as the water-soluble polymer.
Gastric intestinal metaplasia and gastric cancer are associated with Helicobacter pylori, but the bacterium often is undetectable in these lesions. To unravel this apparent paradox, intestinal metaplasia, H. pylori presence and the expression of H. pylori virulence genes were quantified concurrently using histology, in situ hybridization and immunohistochemistry. H. pylori was detected inside metaplastic, dysplastic, and neoplastic epithelial cells, and cagA and babA2 expression was co-localized. Expression of cagA was significantly higher in patients with IM and adenocarcinoma than in controls. The preneoplastic &#39;acidic&#39; MUC2 mucin was detected only in the presence of H. pylori, and MUC2 expression was higher in 1M, dysplasia and cancer. These findings are compatible with the view that all stages of gastric carcinogenesis are fostered by persistent intracellular expression of H. pylori virulence genes, and especially cagA, inside MUC2-producing precancerous gastric cells and pleomorphic cancer cells. The invention further relates to virulence genes of H. pylori such as, but not limited to, an invA or invE gene, portions thereof, and sequences that hybridize or 15 are complementary with, the invA or invE gene. The gene may be isolated or produced recombinantly and used to create expressed product for the treatment and/or prevention of H. pylori infection.
In addition to the localized multi needles of number, shape, lengths and sizes we could:    1. Perhaps use magnetized particles in the nano shells/or retro virus/ or bis peptides or combination to move a solution/swarm of these particles toward the concentration of the infection or where the infection is most virulent and stubborn and most importantly where it is starting to infect a critical organ, eg. hemorrhagic fever.     2. Use radio active particles to track the position of the swarm/solution (of nano shells or retro viruses or bis peptides or combination) spread/concentration to know when (guesstimate) is best to electrically stimulate.     3. Then when the (i) nano shells or retro viruses or bis peptides or combination are next to or bonded/linked/connected to the protein or other mechanism on the cell membrane of the (ii) antibiotic resistant/or virulent bacteria/virus, we could use electrical stimulus to cause (i) to fuse into (ii).     4. Finally we could create a bis peptide that carries (linked/connected/bonded) on one end to nano shells and/or retro viruses (possibly multiple), and on the other end (amine/carboxyl)s specifically designed to bond/link/connect to the antibiotic resistant or virulent bacteria/virus but not to affect any human cells.     5. We could use epigenetic drugs (molecular switches) such as methylation to turn off the genes (or other organism parts) responsible for the increase in antibiotic resistance and also virulence. Or perhaps acetylation, which might turn on the gene to be antibiotic resistant.  Whichever works. We prefer this treatment because it is less invasive, after our solution/swarm has delivered the epigenetic drugs to take away the antibiotic resistance and or virulence, we can administer less strong versions of antibiotics and end the eternal war to out evolve the ever growing resisrance of bacteria/viruses to resistance.     6. We could design nano shell decoys (to have a similar surface as human cells - study what mechanism the specifically viruses but also bacteria - activate their attack instincts; attracts them to seek and infect human cells). Or retro virus and or nano shells and or bis peptide decoys that either fills up their binding site or when attacked, and or deliver epigenetic drug -a chemical that is lethal (perhaps disabling key survival bacteria/virus parts - that does not necessarily affect the bacteria/viruses outer cell membrane so the chemical does affect the human patient&#39;s body) to the antibiotic resistant/virulent bacteria/virus, but this chemical if spills outside the bacteria/virus membrane would be dissolved/dispersed into harmless concentration.
The invention relates to click chemistry based chalcone derivatives as well as a preparation method and an application. The compounds are obtained by using 4&#39;-propargyloxy chalcone as a raw material and reacting 4&#39;-propargyloxy chalcone with different substituted azidomethylenebenzene on a benzene ring in the presence of a catalyst, namely an anhydrous cupric sulfate/sodium ascorbate system. The tyrosinase activities of the synthesized new compounds are tested. The experimental results show that the compounds 3a, 8a, 9a and 15a have certain tyrosinase activating activities, and the compounds 10a and 14a have better tyrosinase activating activities and have smaller EC50 than a positive drug 8-methoxypsoralen. The method is mild in reaction conditions and simple and direct in experimental procedures. The click chemistry based chalcone derivatives are applied to preparation of drugs for treating vitiligo.
A group of inventions relates to medical technologies , in particular, to immunotherapy of oncological patients. Based on surface tumor antigens the antitumor vaccine comprises a mixture of surface tumor antigens. A method of preparing antitumor vaccine comprises cultivation of tumor cells isolating surface tumor antigens. Primary culture of live tumor cells prewashed clean from growing medium is subjected to vital for cells protease affect and select released surface tumor antigens. The primary culture of live tumor cells is treated by protease and repeated with intervals required for restoring by cells of the surface tumor antigens. The surface tumor antigens are accumulated until to reach a dose required for vaccination and control a composition of the resulted surface tumor antigens, wherein trypsin can be used as protease. A method of antitumor immunotherapy comprises administration of antitumor vaccine to patient&#39;s organism. The technical result of using said group of inventions is aimed at enhancing effectiveness of oncological diseases treatment due to the increase of antitumor immune response.